Medtronic’s Adaptive DBS System Wins FDA Approval, Pioneering Personalized Parkinson’s

Medtronic has secured FDA approval for its BrainSense Adaptive deep brain stimulation (DBS) system, the first self-adjusting DBS device for Parkinson’s disease. This advanced brain-computer interface technology personalizes therapy in real time by adapting to an individual’s brain activity, reducing the need for manual adjustments. By continuously monitoring and responding to neurological signals, the device enhances symptom management and improves overall patient outcomes.

Built on Medtronic’s Percept DBS platform, the BrainSense Adaptive system represents a major milestone in Parkinson’s treatment, offering a more dynamic and personalized approach to neuromodulation therapy. With over 40,000 patients already using Medtronic’s Percept devices, the company anticipates significant growth in its brain modulation business. The commercial launch of this adaptive technology is expected to be the largest rollout of brain-computer interface technology to date, reinforcing Medtronic’s leadership in the neuromodulation space.